Olink Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease - Seite 2

“We are tremendously excited to add this rich dataset, revealing important protein-disease associations, to the Olink Insight platform which represents a significant realization of the potential of the UK Biobank data while also further reducing the barrier to access,” says Ida Grundberg, Chief Scientific Officer at Olink. “These data provide essential insights into the biology of disease, allowing researchers to better understand their findings and accelerate the understanding of disease progressions and treatment effects.”

The open-access disease risk data library is another example of Olink’s active partnership with the scientific community to advance our understanding of how individual differences impact disease progression and treatment. Together with industry leading proteomics products and services, Olink is committed to delivering complete end to end solutions that help researchers realize the promise of precision medicine.

Learn more about the open-access disease data in the Olink webinar.

Learn more about Olink Insight at Insight.olink.com.

Learn more about Olink’s next-generation proteomics technologies at Olink.com.

Investor contact

Oskar Hjelm
Chief Financial Officer
Mobile: [phone]
[e-mail]

Media contact

Michael B. Gonzales, PhD
Vice President, Global Marketing
Mobile: [phone]
[e-mail]

About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

Forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.